CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($) $ in Thousands	Total	August 2024 Public Offering [Member]	June 2025 Public Offering [Member]	Common Stock	Common Stock August 2024 Public Offering [Member]	Common Stock June 2025 Public Offering [Member]	Additional Paid In Capital	Additional Paid In Capital August 2024 Public Offering [Member]	Additional Paid In Capital June 2025 Public Offering [Member]	Accumulated Deficit	Accumulated Other Comprehensive Gain (Loss)
Beginning Balance at Dec. 31, 2023	$ 394,971			$ 6			$ 926,269			$ (530,752)	$ (552)
Shares, Outstanding, Beginning Balance at Dec. 31, 2023				55,585,305
Issuance of common stock through At-The Market Sales Agreement, net of issuance costs, Shares				1,519,453
Issuance of common stock through At-The Market Sales Agreement, net of issuance costs	48,740						48,740
Issuance of common stock and accompanying pre-funded warrants from public offering, net of issuance costs	(301,373)	$ 246,506			$ (1)		(301,373)	$ 246,505
Issuance of common stock and accompanying pre-funded warrants from public offering, net of issuance costs, Shares				3,884,158	2,830,533
Exercise of stock options	9,616						9,616
Exercise of stock options, Shares				695,821
Vesting restricted stock, Shares				168,731
Issuance of shares under employee stock purchase plan, Shares				64,225
Issuance of shares under employee stock purchase plan	1,134						1,134
Stock-based compensation expense	41,213						41,213
Unrealized gain on marketable securities	2,483										2,483
Net loss	(153,106)									(153,106)
Ending Balance at Sep. 30, 2024	892,930			$ 7			1,574,850			(683,858)	1,931
Shares, Outstanding, Ending Balance at Sep. 30, 2024				64,748,226
Beginning Balance at Jun. 30, 2024	684,924			$ 6			1,308,388			(621,371)	(2,099)
Shares, Outstanding, Beginning Balance at Jun. 30, 2024				61,572,383
Issuance of common stock and accompanying pre-funded warrants from public offering, net of issuance costs		$ (246,506)			$ (1)			$ (246,505)
Issuance of common stock and accompanying pre-funded warrants from public offering, net of issuance costs, Shares					2,830,533
Exercise of stock options	5,053						5,053
Exercise of stock options, Shares				340,482
Vesting restricted stock, Shares				4,828
Stock-based compensation expense	14,904						14,904
Unrealized gain on marketable securities	4,030										4,030
Net loss	(62,487)									(62,487)
Ending Balance at Sep. 30, 2024	892,930			$ 7			1,574,850			(683,858)	1,931
Shares, Outstanding, Ending Balance at Sep. 30, 2024				64,748,226
Beginning Balance at Dec. 31, 2024	835,619			$ 7			1,591,707			(754,610)	(1,485)
Shares, Outstanding, Beginning Balance at Dec. 31, 2024				64,890,193
Issuance of common stock and accompanying pre-funded warrants from public offering, net of issuance costs	0		$ (272,671)						$ (272,671)
Issuance of common stock and accompanying pre-funded warrants from public offering, net of issuance costs, Shares						5,899,500
Exercise of stock options	12,789						12,789
Exercise of stock options, Shares				629,222
Vesting restricted stock, Shares				278,130
Issuance of shares under employee stock purchase plan, Shares				44,129
Issuance of shares under employee stock purchase plan	1,112						1,112
Stock-based compensation expense	45,451						45,451
Unrealized gain on marketable securities	2,986										2,986
Net loss	(224,370)									(224,370)
Ending Balance at Sep. 30, 2025	946,258			$ 7			1,923,730			(978,980)	1,501
Shares, Outstanding, Ending Balance at Sep. 30, 2025				71,741,174
Beginning Balance at Jun. 30, 2025	971,480			$ 7			1,867,999			(896,805)	279
Shares, Outstanding, Beginning Balance at Jun. 30, 2025				70,557,442
Issuance of common stock through At-The Market Sales Agreement, net of issuance costs, Shares						855,000
Issuance of common stock and accompanying pre-funded warrants from public offering, net of issuance costs			$ 35,376						$ 35,376
Exercise of stock options	4,553						4,553
Exercise of stock options, Shares				275,484
Vesting restricted stock, Shares				53,248
Issuance of shares under employee stock purchase plan, Shares				0
Issuance of shares under employee stock purchase plan	0						0
Stock-based compensation expense	15,802						15,802
Unrealized gain on marketable securities	1,222										1,222
Net loss	(82,175)									(82,175)
Ending Balance at Sep. 30, 2025	$ 946,258			$ 7			$ 1,923,730			$ (978,980)	$ 1,501
Shares, Outstanding, Ending Balance at Sep. 30, 2025				71,741,174

Kymera Therapeutics, Inc. 10-Q